Italia markets close in 1 hour 20 minutes

Roche Holding AG (0QOK.L)

LSE - LSE Prezzo differito. Valuta in CHF.
Aggiungi a watchlist
324,74-7,01 (-2,11%)
Al 06:20PM BST. Mercato aperto.
Schermo intero
Chiusura precedente331,75
Aperto328,00
DenaroN/D x N/D
LetteraN/D x N/D
Min-Max giorno322,70 - 328,15
Intervallo di 52 settimane322,70 - 328,15
Volume23.201
Media VolumeN/D
CapitalizzazioneN/D
Beta (5 anni mensile)0,28
Rapporto PE (ttm)N/D
EPS (ttm)N/D
Prossima data utiliN/D
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Change in the Roche Board of Directors

    Basel, 26 September 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Julie Brown has notified the Board that she will step down as a member of the Roche Board of Directors as she has accepted a management role at another pharmaceutical company. This change will be effective from today. Ms. Brown was elected to the Board of Directors in March 2016 and has since been the Chairwoman of the Audit Committee. Dr. Patrick Frost will chair the Audit Committee on an interim basis until the

  • GlobeNewswire

    European Commission approves Roche’s Vabysmo, the first bispecific antibody for the eye, for two leading causes of vision loss

    Phase III data that showed people with nAMD and DME treated with Vabysmo up to every four months achieved similar outcomes compared to receiving treatment every two months with aflibercept In addition, patients treated with Vabysmo received up to 33% fewer median number of injections compared to aflibercept Reducing the number of eye injections over time could offer a less burdensome treatment schedule for individuals, their caregivers and healthcare systemsVabysmo simultaneously targets and inh

  • GlobeNewswire

    Roche launches a digital PCR system, a powerful new diagnostics platform in the fight against cancer and other diseases

    The Digital LightCycler System is a next-generation digital PCR system that helps clinical researchers better understand the nature of a patient’s cancer, genetic disease or infection.The new system has the potential to find and quantify ultra-rare, hard to detect mutations, leading to early diagnosis and treatment strategies. The Digital LightCycler System is designed for laboratories performing highly sensitive and precise DNA and RNA analysis in areas such as oncology and infectious diseases.